冠科生物

Crown Bioscience is heading to NextGen Biomed in London! From 12-14 March, you'll be able to connect with our experts at booth 72 to help remove the guesswork from your research and development. Don’t miss this opportunity to learn about our high-quality and expansive in vivo, in vitro, and ex vivo preclinical models, and how we can partner with you to quantify the efficacy and pharmacological profile of your drug candidate(s) before they move into the clinic. Schedule a meeting: https://hubs.la/Q038F4D-0 Jonathan Seager, PhD MBA, Sarah Wagner, Eric Obeng, Ph.D., Adrien Mossu, NextGen Biomed by Oxford Global #NGB2025

In today's fast-paced oncology research, translating scientific discoveries into effective treatments is crucial. This blog delves into the powerful role of bioinformatics in preclinical oncology research, highlighting its importance in unlocking innovation-driven insights and streamlining the drug discovery process. Read the full article or listen on the go: https://hubs.la/Q038KCgQ0

Read the new Crown Bioscience newsletter! ?? ??? Get your roundup of some of our latest news, insights, and free resources including: ??Our accreditation to the globally recognized ISO 15189:2022 standard by the College of American Pathologists (CAP). ??How OrganoidXplore? redefines oncology drug screening ??Using multi-omics data to drive early biomarker discovery ????New ADC data and capabilities to support your research ??The power of PDX mouse clinical trials (MCTs) ??Exploring the key applications of organoids ??Meeting with our team at NextGen Biomed London Follow us on LinkedIn to avoid missing our daily updates!

Keeping your oncology drug development in one location is a complex priority, but it doesn’t need to be a complex journey. Protect your materials, studies, and relationships with a full suite of cutting-edge services at Crown Bioscience UK. We remove the location and time zone hurdles so you can make faster, actionable, and more predictive decisions. Take the first step! https://hubs.la/Q038xPlY0

Unlock deeper insights with our multi-oimc profiling services, which combine genomics, transcriptomics, and proteomics to reveal clearer insights, faster. Using cutting-edge technology and expert bioinformatics, we deliver high-quality, reproducible data to help drive: ?Comprehensive biomarker discovery ?Mechanism-of-action elucidation ?Precision medicine & patient stratification Explore how our multi-omics can advance your work. https://hubs.la/Q03893BH0

Our panel of experts were delighted to be joined by industry colleagues at our Advancing Immuno-Oncology event in London. Attendees had the opportunity to delve into the latest advancements in preclinical models for immunotherapies, including antibody-drug conjugates and immune-mediated cellular therapies. Didn't get the chance to meet us in person? You can still learn how advanced in vitro, in vivo, and ex vivo models can be leveraged to optimize target selection, evaluate immune-modulating mechanisms, and de-risk clinical translation. ?? https://hubs.la/Q038bPkW0

Targeted gene panels are reshaping the future of oncology research, providing a strategic and focused approach to genomic testing. These panels focus on cancer-specific genes, offer quicker results, and are more cost-effective, so researchers can streamline drug development. Read our latest blog or listen on the go, to understand the transformative role of targeted gene panels in cancer research and precision medicine. https://hubs.la/Q037XfFx0

How do tumors evolve and what does that mean for personalized medicine? Our latest blog post explores how longitudinal multi-omics studies are powerful in unraveling the intricacies of tumor progression and therapy response. Researchers can uncover early signs of resistance, fine-tune treatments, and drive truly personalized medicine. This comprehensive, real-time approach promises to unlock the full potential of multi-omics in precision oncology. Read the full article or listen on the go. https://hubs.la/Q037XfSN0

Unlock the full potential of your oncology research with Crown Bioscience’s clinically relevant PDX models. Our extensive, fully annotated collection preserves patient tumor heterogeneity, delivering predictive, data-driven insights to optimize drug development. From single-agent studies to combination therapies, our PDX platform offers unmatched precision to accelerate your breakthroughs. Find the right model for your research today! https://hubs.la/Q037v8xV0

Join us as we discuss how PDX, MCT, pretreated models, organoid-based screening, and advanced biomarker analysis can enhance decision-making in oncology drug development. Through real-world case studies and expert insights, you’ll gain a deeper understanding of how to optimize your preclinical and translational research strategies. Reserve your seat now and be part of the conversation! ?? https://hubs.la/Q037wVC70